Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prucalopride - Shire-Movetis

Drug Profile

Prucalopride - Shire-Movetis

Alternative Names: R 093877; R 108512; R 93877; Resolor; Resotran; Resotrans; Rezolor; SHP555; SPD-555

Latest Information Update: 21 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen
  • Developer Janssen; Shire-Movetis NV; University of Calgary
  • Class Amides; Benzofurans; Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II/III Diabetic gastroparesis
  • No development reported Postoperative ileus

Most Recent Events

  • 18 Oct 2018 The US FDA's Gastrointestinal Drugs Advisory Committee recommends approval of prucalopride for Constipation
  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Janssen completes a phase II/III trial in Diabetic gastroparesis in Canada (PO) (NCT02031081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top